CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

trevogrumab

mAbexperimental

Trevogrumab is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. — Wikipedia

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2012 (NCT01507402)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • regn1033
  • regn-1033
  • trevogrumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03710941Phase 2Feb 19, 2019Regeneron
NCT02943239Phase 1Dec 1, 2016Regeneron
NCT02741739Phase 1Mar 1, 2016Regeneron
NCT01963598Phase 2Nov 1, 2013Regeneron, Sanofi
NCT01910220Phase 1Aug 1, 2013Regeneron, Sanofi
NCT01720576Phase 1Oct 1, 2012Regeneron, Sanofi
NCT01507402Phase 1Jan 1, 2012Regeneron, Sanofi
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RegeneronFor profit7722012
SanofiFor profit4022012
2 organizations
Page 1 / 1